Page last updated: 2024-12-07

cobaltiprotoporphyrin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cobaltiprotoporphyrin (CoPP) is a synthetic metalloporphyrin that has been studied for its potential use in various medical applications. It is synthesized by replacing the iron atom in protoporphyrin IX with cobalt. CoPP has shown promise in treating a variety of diseases, including cancer, viral infections, and parasitic diseases. Its effects are attributed to its ability to act as an electron acceptor and a photosensitizer, leading to the generation of reactive oxygen species (ROS) that can damage and kill cancer cells. CoPP is also being investigated for its potential to inhibit the growth of viruses and parasites. The unique properties of CoPP, particularly its ability to generate ROS upon exposure to light, make it a promising candidate for photodynamic therapy (PDT). PDT is a minimally invasive treatment that uses light and a photosensitizer to destroy cancer cells. CoPP's ability to accumulate in tumor cells and its strong absorption of light make it an ideal photosensitizer for PDT. Research on CoPP is focused on understanding its mechanisms of action, optimizing its delivery and targeting, and evaluating its safety and efficacy in various clinical applications.'

cobaltiprotoporphyrin: RN given refers to cobalt protoporphyrin IX [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID108007
MeSH IDM0050059

Synonyms (11)

Synonym
14325-03-2
cobalt protoporphyrin ix
cobaltiprotoporphyrin
cobalt protoporphyrin
63aan3jdze ,
nsc 267101
unii-63aan3jdze
cobaltate(2-), (7,12-diethenyl-3,8,13,17-tetramethyl-21h,23h-porphine-2,18-dipropanoato(4-)-kappan21,kappan22,kappan23,kappan24)-, dihydrogen, (sp-4-2)-
cobaltate(2-), (7,12-diethenyl-3,8,13,17-tetramethyl-21h,23h-porphine-2,18-dipropanoato(4-)-n21,n22,n23,n24)-, dihydrogen, (sp-4-2)-
3-[18-(2-carboxylatoethyl)-7,12-bis(ethenyl)-3,8,13,17-tetramethylporphyrin-21,23-diid-2-yl]propanoate;cobalt(2+);hydron
3-[(1z,4z,10z,14z)-18-(2-carboxyethyl)-7,12-bis(ethenyl)-3,8,13,17-tetramethylporphyrin-21,22,23,24-tetraid-2-yl]propanoic acid;cobalt

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Our results suggest that at least P450IIB1-dependent metabolism of OTA leads to its detoxication and that OTA itself may be toxic in some circumstances or that other pathways are responsible for its activation."( Effect of cytochrome P450 induction on the metabolism and toxicity of ochratoxin A.
Gelboin, HV; Omar, RF; Rahimtula, AD, 1996
)
0.29

Compound-Compound Interactions

ExcerptReferenceRelevance
"In vitro analyses of proliferation and apoptosis were performed on primate T cell cultures, following incubation with the immunosuppressive drugs MPS or CsA, alone or in combination with CoPP."( In vitro and in vivo immunomodulatory effects of cobalt protoporphyrin administered in combination with immunosuppressive drugs.
Ancona, E; Besenzon, F; Bosio, E; Calabrese, F; Cozzi, E; Dedja, A; Polito, L; Rigotti, P; Seveso, M; Tognato, E; Vadori, M; Valente, M, 2010
)
0.36
"In vitro results suggest that co-administration of CoPP with CsA or MPS increases immunosuppressive effects of these drugs when combined with CoPP."( In vitro and in vivo immunomodulatory effects of cobalt protoporphyrin administered in combination with immunosuppressive drugs.
Ancona, E; Besenzon, F; Bosio, E; Calabrese, F; Cozzi, E; Dedja, A; Polito, L; Rigotti, P; Seveso, M; Tognato, E; Vadori, M; Valente, M, 2010
)
0.36

Dosage Studied

ExcerptRelevanceReference
" Four weeks after dosing with either inorganic cobalt or cobalt-protoporphyrin, tissue levels of cobalt were measured by graphite furnace atomic absorption spectroscopy."( Pharmacokinetics of cobalt chloride and cobalt-protoporphyrin.
Rosenberg, DW,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (274)

TimeframeStudies, This Drug (%)All Drugs %
pre-199025 (9.12)18.7374
1990's36 (13.14)18.2507
2000's96 (35.04)29.6817
2010's107 (39.05)24.3611
2020's10 (3.65)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.19 (24.57)
Research Supply Index5.65 (2.92)
Research Growth Index4.84 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.19)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (1.77%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other278 (98.23%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]